InvestorsHub Logo
Followers 60
Posts 5882
Boards Moderated 0
Alias Born 07/17/2009

Re: havocjohn post# 35523

Tuesday, 04/17/2012 3:01:52 PM

Tuesday, April 17, 2012 3:01:52 PM

Post# of 75926
Last week we were at a weekly low of .0091, now we're back up to .0135-.015 range today. That's great, if you ask me. I even picked up more last week @.0109. If I were to sell that purchase today, that would be a profit of $390 on only 150k shares. But guess what, I'm not selling. Here's why...

Unbiased facts:
1) SNDY has ~30 FDA Approved products.
2) They have retired 150m shares in Feb. 2012.
3) Current share structure is low <500m, exact numbers I don't know offhand.
4) SNDY is set to release the SteriTap product line which is already approved for the CE Mark (Sale in Europe, from what we understand this is because it's manufactured in Europe).
5) SNDY reduced their debt by 688k

Expectations:
1) SNDY sales of the MammoView are expected to increase.
2) SNDY expects to be debt free by Q2.
3) Expecting an update regarding CE Mark for the MammoView product line (sale to Europe).
4) Confirmation of additional debt reduction.
5) Confirmation of increased sales and acceptance of MammoView.
6) Release of SteriTap.

Opinion:
All-in-all, this seems to be an outstanding company that is well on their way to becoming profitable. They don't release fluff PR's like many penny stocks, only information that investors should know. They have products that allow early detection of cancer in a minimally invasive manner. The future looks bright with SNDY. It's hard for me to believe SNDY is even trading below .25 given all they have going for them.

My DD says it's a bad idea to sell now, we're going higher. GL

CATS know the difference between REAL Milk and Fake Milk. YouTube video of a Cat taste testing Phase III Recovery vs. Muscle Milk